Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) Gross Profit: 2017-2025

Historic Gross Profit for Organogenesis Holdings (ORGO) over the last 9 years, with Sep 2025 value amounting to $97.7 million.

  • Organogenesis Holdings' Gross Profit rose 10.49% to $97.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $308.3 million, marking a year-over-year decrease of 10.01%. This contributed to the annual value of $366.3 million for FY2024, which is 12.14% up from last year.
  • As of Q3 2025, Organogenesis Holdings' Gross Profit stood at $97.7 million, which was up 87.57% from $52.1 million recorded in Q2 2025.
  • In the past 5 years, Organogenesis Holdings' Gross Profit ranged from a high of $101.0 million in Q2 2024 and a low of $52.1 million during Q2 2025.
  • Its 3-year average for Gross Profit is $82.3 million, with a median of $82.7 million in 2023.
  • In the last 5 years, Organogenesis Holdings' Gross Profit skyrocketed by 90.64% in 2021 and then plummeted by 48.47% in 2025.
  • Organogenesis Holdings' Gross Profit (Quarterly) stood at $95.3 million in 2021, then declined by 7.20% to $88.4 million in 2022, then declined by 18.69% to $71.9 million in 2023, then skyrocketed by 33.00% to $95.6 million in 2024, then increased by 10.49% to $97.7 million in 2025.
  • Its last three reported values are $97.7 million in Q3 2025, $52.1 million for Q2 2025, and $63.0 million during Q1 2025.